Dentroid Pty Ltd

Investment Highlights

Company Overview

Dentroid Pty Ltd is an Australian private company founded in the Australian Capital Territory in 2017 by dentist Omar Zuaiter and robotics engineer Alaa Habeb. It develops dental and medtech devices that combine photonics and miniaturised robotics to address pain and anxiety associated with needles, drills and sprays.

Nuralyte is a patented photobiomodulation device designed to use selected light wavelengths to calm nerves in teeth and gums and induce analgesia, with the aim of reducing or replacing local-anaesthetic injections for common dental procedures. Dentroid-R is a patented robotic platform using a femtosecond laser for precise dental ablation.

Dentroid’s public materials state that five human clinical trials were conducted in 2023–2024 and that Stage 2 Nuralyte trials involving more than 900 patients began in April 2025.

In June 2026, Dentroid and Septodont announced a global development and commercialisation partnership for Nuralyte. The Australian Financial Review subsequently reported a A$32 million capital raising at a A$265 million valuation.

Development status: Dentroid’s website states that its technologies remain in development and have not been verified by a regulator such as the TGA or FDA.

Previous Funding

June 2026 - A$32 million capital raising; A$265 million valuation reported by AFR and SmartCompany. Septodont was named as an investor. AFR also identified Michael Gregg and Dr David Penn as investors.

Products & Services

• Nuralyte — a patented photobiomodulation dental device designed to use controlled light energy to induce analgesia and reduce or replace injections for certain common dental procedures. Dentroid reports five human clinical trials and ongoing Stage 2 clinical work. The first commercial product.
• Dentroid-R — a patented robotic platform using a femtosecond laser, intended to support precise dental ablation without conventional drills or intra-oral water sprays. Dentroid reports successful benchtop testing on extracted teeth.
• Both technologies are development-stage. Dentroid’s public disclaimer states that they have not yet been verified by the TGA or FDA.